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ABSTRACT 
The worldwide prevalence of diabetes has reached 8.5% among adults, and this is 
characterised by elevated glucose concentrations and failing insulin secretion. Furthermore, 
most people with type 2 diabetes are either obese or overweight, with the associated 
dyslipidaemia contributing to the development of insulin resistance and increased 
cardiovascular risk. Here we incubated INS-1 pancreatic β-cells for 72h in RPMI-1640 media, 
or media supplemented with 28mM glucose, 200µM palmitic acid, and 200µM oleic acid as a 
cellular model of diabetic glucolipotoxicity. Illumina HiSeq gene expression analysis showed 
the trace amine-associated receptor (TAAR) family to be among the most highly 
downregulated by glucolipotoxicity. Importantly, MetaCore integrated knowledge database, 
from Clarivate Analytics, indicated potential TAAR impact on insulin secretion through 
adenylyl cyclase signalling pathways. We therefore investigated the effect of TAAR ligands 
on cAMP signalling and insulin secretion, and found that only the branch of the TAAR 
family tree  that is activated by isopentylamine, 2-phenylethylamine, p-tyramine, and 
agmatine significantly increased intracellular cAMP and resulted in increased insulin 
secretion from INS-1 cells and primary mouse islets under normal conditions. Crucially 
however, this enhancement was not evident when the receptor family was downregulated by 
glucolipotoxic conditions. This data indicates that a subset of TAARs are regulators of insulin 
secretion in pancreatic β-cells, and that their downregulation contributes to glucolipotoxic 
inhibition of insulin secretion. As such they may be potential targets for treatment of type 2 
diabetes. 
 
Keywords:  G-protein coupled receptor, adenylyl cyclase, cAMP, glucotoxicity, lipotoxicity 
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1. INTRODUCTION 
Over 80% of patients with type 2 diabetes (T2D) are either overweight or obese, and typically 
this is associated with insulin resistance. Consequently, these patients have both elevated 
blood glucose and free fatty acid concentrations (1). It is known that chronic hyperglycaemia 
inhibits stimulated insulin secretion, but it is the combination of both high sugar and high fat 
that has the largest detrimental effect on -cell function (2). We previously employed 
microarray technology to investigate the effect of glucolipotoxicity upon INS-1 pancreatic -
cell gene expression, and found a wide spectrum of damaging effects including diminished 
insulin secretion, chronic inflammation, increased apoptosis, biological oxidation, and 
dysregulated nucleic acid processing and repair (3). Furthermore, based on ranked statistical 
significance of enrichment following MetaCore integrated knowledge database analysis 
(https://clarivate.com/products/metacore) of that dataset, we also demonstrated the presence 
of disease association with both endocrine and metabolic disorders, which indicates the 
presence of pathways in INS-1 cells with known T2D and obesity aetiology in man (3). 
 
Although microarray technology has proven successful, the development of next generation 
sequencing (RNAseq) technology offers a number of advantages over microarray approaches. 
For example, microarray analysis is limited by the need to rely upon existing knowledge of 
genome sequence, they have high background levels due to cross-hybridization, and a limited 
dynamic range of detection due to both background and saturation of signals. By contrast, 
next generation sequencing strategies analyse total amount of reads that map to the exons of a 
gene, normalised by the length of the exons, and do not have an upper limit for quantification 
(4). The presence and amount of each RNA can therefore be calculated and subsequently 
compared with the amount in any other sequenced sample. In addition, RNAseq data also 
have high levels of reproducibility for both technical (repeated measurements of the same 
sample) and biological (parallel measurements of biologically distinct samples) replicates. 
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Building from our previous work (2,3), we utilised Illumina HiSeq gene expression analysis 
to more accurately define the pathophysiology of type 2 diabetes, with a view to identifying 
potential new targets for therapeutic intervention. Data presented here indicate that 
downregulation of trace amine-associated receptor signalling contributes to the failure of 
insulin secretion that results from chronic exposure of pancreatic -cells to high 
concentrations of glucose and fatty acids. Furthermore, under control conditions, only 
stimulation of family members associated with one specific arm of the TAAR phylogenic tree 
enhanced insulin secretion. We propose that future studies focus on this specific subset of 
family members as potential new therapeutic targets for treatment of type 2 diabetes.  
 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
Antibodies were obtained from Abcam (Cambridge, UK) and Agilent Technologies (Santa 
Clara, CA, USA). Unless otherwise stated, all other chemicals were purchased from Sigma 
Aldrich (St. Louis, MO, USA) or VWR International Ltd (Lutterworth, UK). 
 
2.2 Islet Isolation and INS-1 β-Cell Culture 
Islets were isolated from male CD1 mice by collagenase injection into the pancreatic duct. 
Digested pancreas was washed with MEM-2279 and separated from exocrine tissues by 
centrifuging through a Histopaque 1.077  g/ml gradient. After washing, islets were picked and 
incubated at 37  °C in RPMI-1640 (supplemented with 10% [vol/vol] fetal calf serum, 2 mM 
glutamine and 100U/ml penicillin/ 0.1 mg/ml streptomycin) for 24h prior to further analysis. 
INS-1 rat pancreatic -cells were cultured in RPMI-1640 media, or RPMI media 
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supplemented with 28mM glucose, 200µM oleic acid, and 200µM palmitic acid (GLT 
media), for 72h as detailed previously (2). All animal procedures were approved by the 
King’s College London Ethics Committee and carried out in accordance with the UK Home 
Office Animals (Scientific Procedures) Act 1986. 
 
2.3 Cell Viability 
INS-1 cells were cultured in either RPMI 1640 or GLT media for 72h. Media was aspirated 
and cells washed three times in modified Krebs-Ringer solution (KRB) (125mM NaCl, 
1.2mM KH
2
PO
4
, 5 mM KCl, 2mM Mg SO
4
, 1mM CaCl
2
, 1.67mM glucose, 0.1% BSA, 
25mM HEPES, pH7.4). Cells were then incubated in KRB media supplemented with a final 
concentration of 5µM Calcein AM Cell Viability Dye (ThermoFisher) for 1h, before being 
washed in KRB for a final time. Cell viability was measured via fluorescence, with excitation 
and emission at 490nm and 520nm respectively.  
 
2.4 RNA Isolation  
Cells were incubated in the appropriate conditions for 72h, harvested and RNA extracted 
using an RNA isolation kit (Life Technologies, UK). RNA integrity was assessed using a 
2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA), with all samples analysed in 
this study having a RIN score >8. Samples for transcriptome analysis were prepared using a 
Truseq™ RNA Sample Prep Kit (Illumina Inc., San Diego, CA, USA) according to the 
manufacturer’s recommendations. Briefly, mRNA was isolated from >5 µg of total RNA 
using oligo (dT) magnetic beads. mRNA was cut into short fragments by adding 
fragmentation buffer. First-strand cDNA was synthesized using random hexamer-primers, 
taking these short fragments as templates. RNaseH, buffer, dNTPs, and DNA polymerase I 
was used to synthesize second-strand cDNA. Short fragments were purified with Takara’s 
PCR extraction kit (Takara Bio, Inc.). Sequencing adapters were ligated to short fragments 
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and resolved by agarose gel electrophoresis. Fragments were then selected, purified, and 
subsequently PCR amplified to create the final cDNA library template. 
 
2.5 Next Generation Sequencing 
Library was generated from the fragmentation of mRNA in small pieces using divalent 
cations under elevated temperature, with the fragments converted to first strand cDNA using 
reverse transcriptase and random primers. Subsequently the RNA template was removed and 
a replacement cDNA strand synthesized, generating a double strand-cDNA. The fragments 
were then end-repaired, in a process that converts the overhangs into blunt ends, using T4 
DNA polymerase and Klenow DNA polymerase. Adapters were then ligated to the DNA 
fragments, preparing them to be hybridized to a single read flow cell. cDNA samples were 
purified on a gel to select a size range of templates (around 200 bp) for downstream 
enrichment. The purified cDNA templates were enriched using PCR to amplify the cDNA in 
the library, using primers that anneal to the ends of the adapters. The library was validated by 
performing a quality control analysis to quantify DNA concentration using Agilent 
Bioanalyzer. Library was then used to perform paired end sequencing over one lane of a flow 
cell on an Illumina HiSeq™ 2000 instrument at a read depth of ~65 million reads per sample.  
 
2.6 Expression Analysis 
In the sequencing process, the Illumina instrument produced quality-scored base calls. The 
sequencing output files (compressed FASTQ files) were then used for the secondary analysis.  
Reads were aligned to an annotated reference genome using Top Hat v 2.0.9: 
http://tophat.cbcb.umd.edu. Reads aligned to exons, genes and splice junctions are counted 
using the reference genome “rn4”, extracted from UCSC 
(http://genome.ucsc.edu/goldenPath/credits.html#rat_credits). Data visualisation and 
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interpretation, calculating gene as well as transcript expression, then reporting differential 
expression, was done using the HTseq-count program: 
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html). Normalization, which 
corrects for in-sample distributional differences within the read counts was performed using 
the program DEseq: 
(http://www.bioconductor.org/packages/devel/bioc/html/DESeq.html).  
Statistical significance of fold changes was calculated by comparing the experimental read 
values to the control samples, with p values adjusted using the Bonferroni formula. 
 
2.7 Pathway identification and visualization 
For comprehensive analysis of biological pathways in which transcripts were differentially 
expressed we combined expression data from the next generation sequencing analysis with 
information in Reactome version 29, (http://www.reactome.org), a knowledgebase of 
biological pathways (5). In order to visualize the networks we used MetaCore version 6.34, 
build 69200 from Clarivate Analytics (http://genego.com), an integrated knowledge-based 
platform for pathway analysis. Data analysis tools were used to generate high-resolution 
images of networks, with details of network objects and interactions provided in the Metacore 
legend. 
 
2.8 Quantitative RT-PCR 
INS-1 cells were trypsinised, washed with cold phosphate-buffered saline (PBS) (13.7 mM 
NaCl, 0.27 mM KCl, 1mM Na
2
HPO
4
, 0.2 mM KH
2
PO
4, 
and pH7.4) and lysed in RNAeasy 
QTL lysis buffer. Total RNA was prepared from lysed cells using RNeasy kit (Qiagen, 
Hilden, Germany) according to manufacturers recommended procedures (Qiagen). cDNA 
was generated from RNA using a standard RT kit (Promega, Madison, WI, USA). qRT-PCR 
reactions were performed using Maxima SYBR Green/ROX qPCR Master Mix 
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(ThermoFisher Scientific, Loughborough, UK) and the following primers: TAAR1 forward 
GAAGGAGTTGAGGAGCAGTATC; TAAR1 reverse AAGACGTCATGAATGCCAGTA; 
TAAR2 forward AATGACTATTCCGGTCGTCAAG; TAAR2 reverse 
CCATCAGCATAAGCCTCTGAA; TAAR3 forward GGTATGCAGAGCTACGAGATTC; 
TAAR3 reverse CATGATGGAGCCAGGAGTAAA; TAAR4 forward 
CATGATCGGAGCGATAGTGATG; TAAR4 reverse 
GTGGTAGCCATGGAGAGAATAAG; TAAR5 forward 
CTCCAAGTTCACAGTCAGGATAG; TAAR5 reverse 
GTAGAGAAAGAAGGCAGTGTAGG; TAAR6 forward 
CAGGAATTTGCATCAGCATCTC; TAAR6 reverse CTCCAGGCCATCAGCATAAA; 
TAAR7b forward TCTGCTCTCAGCCTCATCTA; TAAR7b reverse 
CCAAAGCCAAAGACTGCATAAA; TAAR9 forward CCAAGTTCACCATTTCGGTTTC; 
TAAR9 reverse CTCGTTGGCTCCTGTGTAAA; GAPDH forward 
CATCTCCCTCACAATTCCATCC; GAPDH reverse GAGGGTGCAGCGAACTTTAT. 
Due to the high homology between TAAR7 and TAAR8 only one primer pair (TAAR7) was 
designed to amplify these family members [6]. Target gene mRNA was quantified and 
normalised for GAPDH using an ABI7700 bioanalyzer (Applied Biosystems, Foster City, 
CA, USA). Data were analysed using the ΔΔ
CT
method. 
 
2.9 Western Blotting 
INS-1 cells were lysed, protein separated by SDS-PAGE, then transferred to nitrocellulose as 
described previously (2). Protein was detected using anti-TAAR1 (Abcam, Cambridge, UK) 
primary antibody and polyclonal goat anti-rabbit horseradish peroxidase conjugated 
secondary antibody (Agilent Technologies, Santa Clara, CA, USA).
  
 
2.10 cAMP Determination 
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INS-1 cells were treated with TAAR ligands (either isopentylamine, p-tyramine, 2-
phenylethylamine, agmatine, N,N-dimethylcyclohexylamine, N,N-dimethyloctylamine, or the 
inverse agonist EPPTB) suspended in KRB plus 0.5mM IBMX for half an hour prior to 
cAMP determination. Cells were then lysed in 0.1M HCl according to manufacturer’s 
protocol, and cAMP accumulation level determined using cAMP Select ELISA kit (Cayman 
Chemical Company, Ann Arbour, MI, USA). 
 
2.11 Insulin Secretion 
INS-1 cells were treated with KRB or KRB supplemented with secretagogue cocktail 
(13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM isobutyl-methylxanthine, 
1mM tolbutamide, 10mM leucine, 10mM glutamine) for 2h prior to determination. 
Supernatant was removed and insulin secretion was determined using an ELISA kit as 
detailed previously (2). Size-matched islets were pre-incubated for 1  h at 37  °C in buffer 
containing 2 mM glucose, 2 mM CaCl
2
 and 0.5 mg/ml BSA, pH 7.4. Islets were further 
incubated in buffer containing 2 or 20 mM glucose for 1  h ± stated amine concentration at 
37  °C with gentle shaking. Insulin secretion was measured by radioimmunoassay with an in-
house 
125
I-labelled insulin tracer as previously detailed (7). 
 
2.12 Statistical Analysis 
Results are expressed as mean ± standard error of the mean (n = 3 or more independent 
experiments).  Parameters were compared using one-tailed student t-test assuming equal 
variance, with statistical significance determined using an alpha value of 5%. A p value 
below 0.05 was therefore considered to be statistically significant. 
 
 
3. RESULTS 
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3.1 Impact of Glucolipotoxicity upon -Cell Protein Classes 
In order to better understand the mechanisms by which chronic exposure to high glucose and 
fatty acids alters cellular function, we incubated INS-1 rat pancreatic -cells for 72h in 
RPMI-1640 media, or media supplemented with 28mM glucose, 200M oleic acid, and 
200M palmitic acid (GLT media), conditions previously characterised for the study of the 
effects of glucolipotoxicity upon insulin secretion (2). Total RNA was isolated and 
sequencing undertaken using an Illumina HiSeq™ 2000 instrument (Illumina Inc., San 
Diego, CA, USA). Genes differentially expressed in conditions of high glucose/high fat 
relative to control (with p<0.05) were analysed using PANTHER gene ontology software 
(http://www.pantherdb.org) in order to determine those that have the greatest differential 
expression associated with glucolipotoxicity. The program calculates the number of genes 
that are enriched within a specific pathway, and the associated statistical significance of 
enrichment. Enrichment is considered statistically significant when there are more genes in 
the list associated with a particular pathway than would be expected by chance based on the 
total number of genes associated with that pathway. As can be seen (Table 1), G-protein-
coupled receptor (GPCR) signalling was found to be the most significant of any specific 
protein class differentially expressed. We therefore focussed the remainder of the current 
study on GPCR families that are differentially expressed within our RNAseq dataset, and 
which might therefore contribute to -cell dysfunction caused by glucolipotoxicity. 
 
3.2 Trace Amine-Associated Receptor Family Downregulation by Glucolipotoxicity 
Of note, among the GPCR families differentially regulated by high glucose and fatty acids, 
the trace amine-associated receptor (TAAR) family stands out as all members are 
downregulated following 72h incubation in GLT media. Indeed, TAAR3, 4, 5, 6, 7a, 7b, 7c, 
7d, 7e, 7g, 7h, 8b, 8c and 9 are downregulated to the level of detection sensitivity (Fig. 1a). 
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As we had incubated cells under control, high glucose, high fatty acid, and high glucose plus 
high fatty acid conditions we were also able to determine the extent to which glucose and 
fatty acids drive down regulation both individually and together. Glucose and fatty acids each 
drive down expression significantly (p<0.05 in all cases, except for TAAR1 in high fatty 
acid). Importantly however, combination treatment with high glucose and high fat (GLT 
media) had the largest downregulation on all TAAR members. 
 
In order to validate these results, we next performed independent qRT-PCR analysis of the 
TAAR family members TAAR1, 2, 3, 4, 5, 6, 7b and 9 (Fig. 1b) from cells incubated +/- 
GLT media for 72h. In all cases TAAR expression was significantly downregulated by GLT 
media, with values ranging from 30.2% ± 12.0% (p=0.033) for TAAR4, to 60.8% ± 10.2% 
(p=0.002) for TAAR7b. RNA does not always correspond to protein expression however, so 
it is also important to quantify protein expression between control and GLT conditions. 
Therefore, INS-1 β-cells were again cultured +/- GLT media for 72h, cells lysed, and 
immunoblotted using antibody against TAAR1 (Fig. 1c), the only TAAR family member for 
which a commercial antibody was available (Abcam, Cambridge, UK). Densitometry 
analysis indicated that TAAR1 protein expression was downregulated by 42.6% ± 9.1% in 
comparison to GLT media (p=0.0017). Furthermore, these data are not the result of altered β-
cell viability resulting from exposure to glucolipotoxic media, as INS-1 cells incubated for 
72h in GLT media had 103.7 ± 3.4% cell viability relative to RPMI-1640 media control (data 
not shown). 
 
3.3 Impact of Glucolipotoxicity upon the TAAR1 Interactome 
In order to better understand how TAAR family downregulation might impact upon 
pancreatic -cell function, non-biased network analysis was performed using the MetaCore 
integrated knowledge database of pathways (https://portal.genego.com). Expression data 
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from the RNAseq analysis files was used as the input list for generation of biological 
networks using the Analyze network algorithm with default settings. By so doing we were 
able to generate a bespoke network of molecules predicted to interact with the most 
extensively characterised member of the TAAR family, TAAR1 (Figure 2). Those genes 
upregulated by GLT in our experiments are indicated by an adjacent red circle in the 
interactome, whereas those genes that are downregulated are indicated by a blue circle. Our 
data indicate that when TAAR1 (shown as TAR1 in Figure 2) is downregulated by 
glucolipotoxicity there are both positive and negative downstream effects on GPCR 
signalling through G pathways. Specifically, stimulatory Gs protein is downregulated, 
whereas inhibitory Gi protein is upregulated. The consequence of these complementary 
effects would be a concerted negative downstream action upon adenylyl cyclase. 
Furthermore, such an effect would reduce ATP conversion to cAMP, a molecule known to 
amplify insulin secretion from pancreatic β-cells (8). 
 
3.4 Effect of TAAR Ligands upon cAMP Level and Insulin Secretion 
The TAAR1 interactome is consistent with previous literature that has indicated an 
association between TAAR1 signalling and adenylyl cyclases via G
αs 
proteins (9). We 
therefore sought to determine whether physiological TAAR ligands could enhance insulin 
secretion via cAMP pathways in -cells. INS-1 cells were grown in RPMI-1640 media, then 
washed and incubated in KRB and 0.5mM IBMX, or KRB and 0.5mM IBMX supplemented 
with the trace amine ligands, isopentylamine (TAAR3), p-tyramine (TAAR1 and TAAR4), 2-
phenylethylamine (TAAR1 and TAAR4), agmatine (putative TAAR6 and TAAR8 ligand), 
N,N-dimethylcyclohexylamine (TAAR7, TAAR8 and TAAR9 isoforms), and N,N-
dimethyloctylamine (TAAR7 isoforms) at a single final concentration of 10µM for direct 
comparison, or the TAAR1 inverse agonist EPPTB at a concentration of 10nM, for 30 min.  
Cells were lysed in 0.1M HCl and cAMP determined via select ELISA. Isopentylamine was 
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found to significantly increase the level of cAMP by 3.5 ± 0.6 fold (p=0.02) relative to 
control, whilst p-tyramine increased cAMP accumulation by 3.8 ± 0.5 fold (p=0.01), 2-
phenylethylamine by 4.1 ± 0.7 fold (p=0.02) and agmatine by 2.8 ± 0.3 fold (p=0.005) 
respectively. By contrast, incubation with EPPTB decreased the cAMP level to 0.78 ± 0.04 
(p=0.004), whilst N,N-dimethylcyclohexylamine and N,N-dimethyloctylamine also resulted 
in a modest decrease in cAMP level to 0.90 ± 0.01 (p=0.003) and 0.83 ± 0.05 (p=0.01) 
respectively (Figure 3a). 
 
In order to determine how this might relate to insulin secretion, INS-1 cells were cultured to 
70% confluency, washed, and then incubated with either KRB or KRB secretagogue cocktail 
(supplemented with 13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM isobutyl-
methylxanthine, 1mM tolbutamide, 10mM leucine, 10mM glutamine) along once more with, 
where indicated, isopentylamine, p-tyramine, 2-phenylethylamine, agmatine, N,N-
dimethylcyclohexylamine, or N,N-dimethyloctylamine at a final concentration of 10µM, or 
the inverse agonist EPPTB at a concentration of 10nM, for 2h. Insulin secretion was 
determined by ELISA (Mercodia, Uppsala, Sweden) and normalised to cellular protein 
content. Data is presented as fold change relative to stimulated control from the 
corresponding experiment (Figure 3b). Consistent with our cAMP data, N,N-
dimethylcyclohexylamine had no significant effect upon secretagogue-stimulated insulin 
secretion, whilst N,N-dimethyloctylamine and the TAAR1 inverse agonist, EPPTB, decreased 
secretion by 13.2%  5.0% (p=0.029) and 18.2%  4.0% (p=0.005) respectively. By contrast, 
isopentylamine, p-tyramine, and 2-phenylethylamine significantly increased secretagogue-
stimulated insulin secretion by 16.8%  5.1% (p=0.0149), 23.3%  8.7%, (p=0.045), and 
26.5%  7.1% (p=0.0155) respectively. Agmatine also caused a modest increase in stimulated 
insulin secretion by 16.0%  6.9%, albeit this was just outside statistical significance 
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(p=0.056). There was, however, no significant change in unstimulated insulin secretion for all 
treated ligands compared to control. 
 
In order to determine whether those ligands that enhance cAMP and insulin secretion under 
standard conditions might make suitable drug candidates for the treatment of T2D, we then 
repeated the insulin secretion experiments in glucolipotoxic conditions. Our results show that 
in the absence of ligands, GLT media decreased insulin secretion to 26.7  9.6% of control 
stimulated secretion values (Figure 3c). Crucially, however, all of the previously observed 
increases in insulin secretion that had been seen under standard media conditions were no 
longer observed when cells had been incubated in GLT media, where a decrease in TAAR 
expression is seen. 
 
Given the clear split in cellular response to the different amine ligands under standard 
conditions, between those that enhance cAMP signalling and insulin secretion and those that 
do not, we then sought to determine whether this might be explained by evolutionary 
divergence within the TAAR family. The resulting phylogenetic tree, complete with ligand 
responsiveness mapped alongside this, is shown in Figure 3d.  
 
The above data is fully consistent with a role for TAAR family members 1-4 in insulin 
secretion. However, transformed -cell lines are not always fully representative of primary -
cell biology, and so it is important to determine whether these findings are indicative of 
whole animal physiology. In order to address this point pancreatic islets were isolated from 
CD1 mice, then incubated with the monoamine oxidase inhibitor pargyline (in order to 
prolong the half-life of administered tyramine) and the indicated concentration of p-tyramine, 
and insulin secretion determined (Figure 4). p-tyramine increased glucose-stimulated insulin 
secretion by 33.2% ± 20.3% (p=0.199), 83.2% ± 11.8% ( p=0.004), 41.2% ± 23.4% 
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(p=0.156) and 47.8% ± 26.8% (p=0.067) at concentrations of 0.1µM, 1µM, 10µM and 100µM 
respectively. This U-shaped curve and decrease in tyramine effect likely represents a loss of 
selectivity seen at concentrations of tyramine greater than 10M, where there are known to 
be competing mechanisms from interaction with other pharmacological targets.  
 
 
4. DISCUSSION 
Through Illumina HiSeq analysis of RNA that was extracted from -cells exposed to 
conditions of diabetic glucolipotoxicity, we have been able to identify those genes that 
become dysregulated following chronic exposure to high glucose and fatty acid levels. When 
analysed for differential expression, receptor signalling showed the highest statistical 
significance. This indicates that the molecules involved in glucolipotoxicity are likely 
primarily implicated in signalling pathways, in regulating transcription factors binding, and in 
molecular transport. The former is consistent with our previous microarray experiments, 
where we identified a novel role for TNFR5 signalling in initiating NF-B and STAT1 
transcription factor activation and subsequent islet inflammation that leads to -cell apoptosis 
(3). However, our current data shows that GPCR signalling was the most significant of any 
specific protein class differentially expressed. Within this category, the TAAR family were 
all substantially downregulated, many to the level of our assay detection sensitivity, 
following 72h culture in GLT media. This makes the TAAR family prime candidates for 
participation in insulin stimulus-secretion coupling, which is significantly decreased by 
glucolipotoxicity.  
 
TAARs were first identified in 2001 as receptors for endogenous trace amine ligands 
including p-tyramine, 2-phenylethylamine and tryptamine (9,10). Humans possess six 
functional TAARs, mice have fifteen, and rat seventeen. All, except TAAR1, have previously 
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been shown to also function as olfactory receptors (11-13). In the case of TAAR1 the 
receptor signals via G
αs
 proteins to increase intracellular cAMP concentration (9,14,15). In the 
olfactory epithelium however, all TAARs appear to couple to G
olf
, though this also associates 
with adenylyl cyclase to increase cAMP (11,16,17). TAARs have also been implicated in 
neuropsychiatric disorders, where they modulate monoaminergic neurotransmission (18,19).  
 
Importantly, TAAR1 has previously been shown to be expressed in pancreatic β-cells from 
both human islets and mouse MIN-6 cells (18,20,21). Indeed, the discovery of the TAAR 
family was in part due to screening of pancreatic tumour cell lines (9). Administration of the 
potent, although non-selective, TAAR1 ligand 3-iodothyronamine strongly enhanced insulin 
secretion from MIN-6 cells (20). More recent studies with highly selective agonists have 
confirmed a TAAR1-mediated enhancement of glucose-stimulated insulin secretion, an effect 
observed in both INS-1 cells and isolated human islets (21). Importantly TAAR1 agonists 
maintain efficacy in vivo, where improved glucose tolerance has been observed, along with 
increased insulin secretion in response to a glucose challenge (21). Furthermore, single 
nucleotide polymorphisms of TAAR1 that result in altered signal transduction were recently 
reported in a sub-set of patients exhibiting impaired insulin secretion (22). These studies 
therefore suggest that TAAR1 may be a novel therapeutic target to treat type 2 diabetes. 
Crucially however, other TAAR isoforms have not previously been studied in this context. 
 
In order to further explore their potential as possible drug development targets, we 
investigated the effect of endogenous ligands of the wider TAAR family upon insulin 
secretion from INS-1 -cells and primary mouse islets, with cells either incubated under 
standard conditions or following 72h incubation in GLT media. Pharmacological studies of 
human, mouse and rat TAARs have shown that p-tyramine and 2-phenylethylamine activate 
TAAR1 and TAAR4 (10,19,23). Isopentylamine is a reported endogenous agonist for 
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TAAR3 (11), while agmatine is only currently described as an agonist for TAAR 13c that has 
currently only been found to be expressed in zebra fish (24). The diamine binding site 
through which agmatine interacts with TAAR13c is, however, conserved in both human and 
rodent TAAR6 and TAAR8 isoforms (24,25) making them potential sites through which 
agmatine effects might be mediated. The N,N-dimethylalkylamines, meanwhile, are agonists 
at TAAR7 and TAAR9 isoforms (16). Our data show that under control conditions it is not 
only TAAR1 stimulation that has the ability to influence glucose metabolism, but in fact 
ligands that activate TAAR1, TAAR3, and TAAR4. By contrast EPPTB, an inverse agonist 
for TAAR1, and trace amine ligands that bind to TAAR7 and 9 had no positive effect upon 
secretagogue-stimulated insulin secretion. The positive effect of ligand activation in control 
conditions is also consistent with our cAMP data, where higher insulin secretion was 
reflected by higher intracellular cAMP concentrations. This was further validated by the 
modest, albeit statistically non-significant, increase in insulin secretion following agmatine 
stimulation, which similarly reflected the smaller effect on cAMP increase. In addition, the 
inverse agonist EPPTB decreased cAMP levels and insulin secretion, further supporting the 
link between cAMP level and secretion data. 
 
TAARs 1-4 form one of the two major branches of the TAAR phylogenetic tree known as 
primary amine detectors. This suggests a conserved genetic ancestry possibly involving the 
functional ability to regulate cAMP conversion from ATP through primary amine binding 
(26). As shown (Figure 3d), it is only ligands for these particular TAARs that significantly 
enhance insulin secretion, whilst those that have no positive effect upon insulin secretion act 
on a separate branch of the phylogenetic tree. Agmatine would appear to be one possible 
exception to this rule as it has only been previously described as an agonist for TAAR13c, a 
receptor that has a binding site conserved with TAAR6 and TAAR8. Zebrafish TAAR13c is 
however nevertheless present on the same branch of the phylogenetic tree as those receptors 
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capable of regulating insulin secretion (27), and while agmatine is known not to interact with 
TAAR1 (28) it is conceivable that agmatine may activate other TAARs of this conserved 
mammalian branch of the tree that are currently incompletely characterized. However, this is 
an area that requires further systematic study, particularly in light of agmatine's known poly-
pharmacology. As such the effects we observed in response to agmatine cannot be 
definitively ascribed to one or more TAAR-family members at this time. 
 
The above studies are consistent with TAAR representing a novel therapeutic target for the 
treatment of type 2 diabetes. Furthermore, previous work has shown TAAR1 agonists also 
have beneficial effects on nutrient-induced hormone secretion from the gastrointestinal tract, 
regulating glucagon-like peptide 1 (GLP-1) and peptide YY secretion from intestinal L-cells 
(21), and somatostatin secretion from the stomach D-cells (29). Such potential benefit could 
be negated, however, by our observation that glucolipotoxicity decreases the expression of 
the receptors through which such effects are mediated. Indeed, our data shows that the ability 
of these ligands to enhance insulin secretion was lost when INS-1 cells were cultured in GLT 
media for 72h. This is in agreement with our expression data, as downregulation of receptor 
expression following exposure to GLT media would reduce the potential for receptor ligand 
binding and the resultant signal transduction which leads to downstream increases in 
secretion. It is worth noting, however, that in other cell types a positive feedback loop has 
been suggested whereby TAAR1 agonists induce increased expression of TAAR1. As such, 
the non-selective TAAR1 agonist methamphetamine increases TAAR1 expression in T 
leukocytes (30), with a similar effect also recently reported in placenta in response to the 
highly selective TAAR1 agonist RO5203648 (31). Should such an effect also occur in 
pancreatic -cells following a longer-term administration than the 2h treatment used here, 
this may allow for TAAR agonists to still be effective and overcome the glucolipotoxicity-
induced decrease in receptor expression. This is an area for future systematic study. In 
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addition, studies on the status of TAAR gene expression in human diabetic patients are also 
needed, although as noted earlier signal-modifying TAAR1 polymorphisms have recently 
been linked to impaired insulin secretion in certain patients (22). 
 
Given that failure of insulin secretion leads to the onset of overt diabetes, this has been a 
primary target for therapeutic intervention since sulfonylurea compounds were first 
introduced as oral antidiabetic agents in the 1950s. Indeed, these compounds remain an 
important pharmacotherapy for the control of glucose homeostasis in patients with T2D to 
this date. However, safety concerns over sulphonylureas have started to arise in recent years, 
not least as their use can result in hypoglycemia and weight gain. In addition, over time they 
also often become less effective. This has therefore resulted in a search for new compounds, 
and especially those that are able to enhance insulin secretion through different mechanisms. 
Unlike sulphonylureas, TAAR1 agonists do not appear to promote hypoglycaemia (21). They 
do however promote weight loss in models of excessive weight gain (18,21), and moreover 
may even normalize binge eating phenotypes (32), offering potential additional benefits over 
current frontline pharmacotherapies. Importantly, TAAR1 has been confirmed in clinical 
trials as a viable, safe, target to which pharmacotherapies can be targeted (33), and as such 
TAAR1directed agents may be beneficial prophylactically in pre-diabetic patients.  
 
Sulphoylureas bind to and close pancreatic -cell K
ATP
 channels, resulting in cell membrane 
depolarisation and subsequent L
c
-type Ca
2+
-channel opening, Ca
2+
 influx, and exocytosis of 
insulin-containing secretory granules (34). More recently incretin mimetics have also been 
employed to enhance insulin secretion. Their mechanism of action is different to 
sulphonylureas as, like TAARs, incretin receptors instead activate stimulatory cell membrane 
GPCRs linked to adenylyl cyclase. This then generates cAMP, which in turn serves to 
amplify glucose-stimulated insulin secretion (35,36). Dipeptidyl peptidase 4 (DPP4) 
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inhibitors, or gliptins, also enhance incretin levels, albeit through inhibition of the enzymatic 
breakdown of incretins (37). Consequently, they also therefore enhance stimulatory GPCR 
signalling.  
 
Whilst incretin mimetics are increasingly being advocated as a safer alternative to enhance 
insulin secretion than sulphonylureas, these too are not without problems. Firstly, 
hyperglycaemia has been shown to significantly reduce expression of -cell incretin receptors 
(38), not unlike our current data showing downregulation of TAARs following exposure to 
glucolipotoxicity. In addition, these drugs need to be administered through subcutaneous 
injection, which is often unpopular with patients. In addition, some patients develop irritation 
at injection sites, further adding to their unpopularity. However, DPP4 inhibitors and TAAR 
agonists can be administered orally, thereby offering a less problematic way to activate 
adenylyl cyclase. Therefore, in conclusion, whilst glucolipotoxic downregulation of TAAR 
family members 1-4 leads to a significant reduction in insulin secretion, and therefore likely 
contributes to T2D pathophysiology, use of new and existing therapies to augment adenylyl 
cyclase activity through receptors linked to heterotrimeric Gs signalling pathways might 
prove effective at offsetting this deficiency.  
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Protein Class p Value 
Receptor 1.88 E-38 
G-protein coupled receptor 1.67 E-24 
RNA binding protein 3.54 E-20 
Ribosomal protein 1.54 E-18 
Signalling molecule 1.28 E-17 
Nucleic acid binding 2.91 E-17 
Transporter 8.91 E-16 
Immunoglobulin 1.13 E-13 
Ion Channel 2.72 E-13 
Cell adhesion molecule 4.58 E-11 
 
Table 1 - Differential expression of protein family classes.  
Comparative analysis of gene expression from INS-1 cells incubated for 72h in RPMI-1640 
media supplemented with or without 28mM glucose, plus 200M oleic acid, and 200M 
palmitic acid. Data is compiled from six independent RNAseq analyses (three per 
experimental group). 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
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Figure 1 – Effect of Glucolipotoxicity on TAAR Family Expression. 
a) INS-1 cells were cultured in RPMI-1640 media, or media supplemented with 28mM 
glucose, 200µM oleic acid and 200µM palmitic acid, or 28mM glucose plus 200µM oleic acid 
and 200µM palmitic acid (GLT) for 72h. RNA was extracted and Illumina HiSeq analysis 
undertaken. Data is expressed as RNA read counts per condition.  
b) INS-1 cells were cultured in RPMI-1640, or GLT media for 72h. RNA was extracted and 
qRT-PCR undertaken using the primers and cycle conditions detailed in the Methods section. 
c) INS-1 cells were grown in RPMI-1640, or GLT media for 72h. Protein was extracted and 
separated by SDS-PAGE, transferred to nitrocellulose, and detected using anti-TAAR1 
primary antibody.  
In all cases data are expressed as mean ± SEM from 3 or more independent experiments. 
*p<0.05 **p<0.005 ***P<0.0005 
 
 
Figure 2 - Network Analysis of TAAR1 Signalling.  
INS-1 cells were cultured in RPMI-1640 media, or media supplemented with 28mM glucose, 
200µM oleic acid and 200µM palmitic acid, (GLT) for 72h. RNA was extracted and Illumina 
HiSeq analysis undertaken. MetaCore software (http://genego.com) was utilised to construct 
an interactome linked to TAAR1 (TAR1). Significantly upregulated genes (Bonferroni 
corrected p value < 0.05) are indicated by an adjacent red circle, whereas downregulated 
genes are indicated by an adjacent blue circle. 
 
 
Figure 3 – Effect of Trace Amines on cAMP and Insulin Secretion. 
a) INS-1 cells were grown in standard growth media before being washed and incubated in 
KRB and 0.5mM IBMX or KRB and 0.5mM IBMX supplemented with either 
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isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), agmatine (Agm), N,N-
dimethylcyclohexylamine (Cyclo), or N,N-dimethyloctylamine (Ctyl) at a final concentration 
of 10µM, or the inverse agonist EPPTB at a concentration of 10nM, for 30 min. Cells were 
lysed in 0.1M HCl and cAMP determined via select ELISA.  
b) INS-1 cells were cultured in standard growth media to 70% confluency, washed, then 
incubated in either KRB [(-) blue] or KRB secretagogue cocktail [(+) red] (containing 
13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM isobutyl-methylxanthine, 1mM 
tolbutamide, 10mM leucine, 10mM glutamine), minus or plus trace amine ligands as 
indicated: isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), agmatine 
(Agm), N,N-dimethylcyclohexylamine (Cyclo), N,N-dimethyloctylamine (Ctyl) at a final 
concentration of 10µM, or TAAR1 inverse agonist EPPTB at a concentration of 10nM for 2 
h. Insulin secretion was then determined by ELISA (Mercodia, Sweden), and normalised to 
cellular protein content. 
 c) INS-1 cells were cultured in RPMI-1640 media, or RPMI-1640 GLT media for 72h. 
Insulin secretion was determined by ELISA assay following incubation ± secretagogue 
cocktail [(-) blue, (+) red], minus or plus trace amine ligands as indicated: isopentylamine 
(Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), or agmatine (Agm) at a final 
concentration of 10µM for 2h, with data normalized to cellular protein content.  
d) TAAR family phylogenetic tree, with trace amine ligand responsiveness mapped 
alongside. 
In all cases data are expressed as mean ± SEM from a minimum of 3 independent 
experiments. *p<0.05 **p<0.005 compared to control. 
 
Figure 4 – Dose-Dependent Effect of p-Tyramine upon Insulin Secretion from Mouse 
Islets. 
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Islets were isolated from CD1 mice, then cultured in RPM1-1640 media for 24h. Islets were 
then incubated in 2mM [(-) blue] or 20mM [(+) red] glucose for 1h, supplemented with 10µM 
paragyline ± p-tyramine at the stated concentration, and insulin secretion determined by 
radioimmunoassay. Dara are expressed as mean ± SEM from a minimum of 5 independent 
experiments. **p<0.005 compared to control stimulated (+) samples. 
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